Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07347418 · ClinicalTrials.gov registry record · Phase 1
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
A Phase 1 study, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT07347418 is a Phase 1 study that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 23 participants.
The verdict
NCT07347418, a Phase 1 study, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduced autologous T cells expressing anti-CD64 chimeric antigen receptors (CAR) expressing tandem CD3ζ and 4-1BB (CD3ζ/4-1BB) costimulatory domains in subjects with refractory or relapsed (R/R) acute myeloid leukemia (AML). This CAR T cell product will be referred to as "CD64 CAR T" which is CD64 directed, autologous, genetically modified CAR T cells. The primary objective of the study is to identify the safety profile and maximum tolerated dose (MTD) of CD64 CAR T in subjects with R/R AML as determined by the defined DLTs using a standard Bayesian Optimal Interval (BOIN) design.
Interventions
- DRUG CD64 CAR T Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-06 |
| Est. Completion | 2032-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07347418
The ClinicalTrials.gov registry entry for NCT07347418 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD64 CAR T Cells is the first listed.
NCT07347418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07347418 about?
NCT07347418 is a clinical study titled "CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML". This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduced autologous T cells expressing anti-CD64 chimeric antigen receptors (CAR) expressing tandem CD3ζ and 4-1BB (CD3ζ/4-1BB) costimulatory domai...
What is the current status of trial NCT07347418?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2026-06. Estimated completion is 2032-06.
What interventions are being tested in trial NCT07347418?
The interventions under investigation include: CD64 CAR T Cells (DRUG).
Who is sponsoring clinical trial NCT07347418?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.